Wang Xing, He Ying-jian, Ying Min, Li Jin-feng, Xie Yun-tao, Wang Tian-feng, Fan Zhao-qing, Fan Tie, Ouyang Tao
Breast Cancer Prevention & Treatment Center, Beijing Cancer Hospital, School of Oncology, Peking University, Beijing 100142, China.
Zhonghua Yi Xue Za Zhi. 2011 Aug 16;91(30):2116-9.
To compare the distant disease-free survival between breast cancer patients with nodal pathological complete response (pCR) and those with nodal residual disease (RD) after neoadjuvant chemotherapy.
The clinical and pathological data of 376 needle biopsy proved node positive breast cancer patients undergoing neoadjuvant chemotherapy were retrospectively analyzed.
The median follow-up time was 24 months (range: 5 - 100). The pCR rate of axillary lymph node was 30.9%. And the three-year distant disease-free survival (DDFS) rates were 91.7% and 78.8% in the patients with axillary lymph node pCR and RD respectively. According to the Log-rank test, there were significant differences in survival curves (P = 0.016). Multivariate analysis showed that the relative risk of DDFS for patients with RD was 2.14 folds of than that of the pCR group (P = 0.047). No significant difference existed between the disease-free survival (DFS) curve in two groups. DDFS had significant differences between the patients with the number of lymph node metastasis ≤ 3 and ≥ 4 in the RD group (P = 0.001).
The distant disease-free survival of node positive breast cancer is associated with the status of axillary lymph node after neoadjuvant chemotherapy.
比较新辅助化疗后淋巴结病理完全缓解（pCR）与淋巴结残留疾病（RD）的乳腺癌患者的远处无病生存率。
回顾性分析376例经针吸活检证实为淋巴结阳性且接受新辅助化疗的乳腺癌患者的临床和病理资料。
中位随访时间为24个月（范围：5 - 100个月）。腋窝淋巴结pCR率为30.9%。腋窝淋巴结pCR和RD患者的三年远处无病生存率（DDFS）分别为91.7%和78.8%。根据对数秩检验，生存曲线存在显著差异（P = 0.016）。多因素分析显示，RD患者DDFS的相对风险是pCR组的2.14倍（P = 0.047）。两组的无病生存（DFS）曲线无显著差异。RD组中淋巴结转移数≤3个和≥4个的患者之间DDFS存在显著差异（P = 0.001）。
淋巴结阳性乳腺癌的远处无病生存与新辅助化疗后腋窝淋巴结状态有关。
